tofacitinib cream (CGB 500)
/ CAGE Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 15, 2025
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=3 | Not yet recruiting | Sponsor: CAGE Bio Inc.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 13, 2025
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
(clinicaltrials.gov)
- P1/2 | N=40 | Completed | Sponsor: CAGE Bio Inc. | Not yet recruiting ➔ Completed
Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
February 05, 2025
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: CAGE Bio Inc.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 3
Of
3
Go to page
1